Do you want to read an article? Please log in or register.
Prescription‑dose stratification improves deep learning‑based VMAT dose prediction in locally advanced NSCLC
Lung Cancer
Related content
Lung Cancer
Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?
Clin Lung Cancer
Watanabe Y, Koide Y, Shimizu H, Aoyama T, Shindo Y, Hashimoto S, Tachibana H, Kodaira T
doi: 10.1016/j.cllc.2025.05.002
RECOMMENDED
Pneumonia
Enhanced prediction of ventilator-associated pneumonia in patients with traumatic brain injury using advanced machine learning techniques
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Sci Rep
Ashrafi N, Abdollahi A, Alaei K, Pishgar M
doi: 10.1038/s41598-025-95779-0
Lung Cancer
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Nat Commun
Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M
doi: 10.1038/s41467-026-68554-6
Lung Cancer
Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Lung Cancer
Ciammella P, Iori F, Borghetti P, Galaverni M, Alì E, Tiseo M, Pagano M, Sepulcri M, Scotti V, GiajLevra N, Marcenaro M, Simoni N, Nardone V, Botti A, Cozzi S, Bruni A
doi: 10.1016/j.lungcan.2025.108718
Lung Cancer
KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort
J Clin Med
Geçgel A, Şahin Çelik B, Peker P, Gökdere ZS, Koca D, Karaca B, Nart D, Göker E
doi: 10.3390/jcm14196826
Lung CancerPleural Diseases
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)
J Clin Med
Djordjevic F, Ljujic K, Stanic N, Nikolic N, Markovic I, Spasic J
doi: 10.3390/jcm14176200
Lung Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
Lung Cancer
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee
J Thorac Oncol
Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV
doi: 10.1016/j.jtho.2025.11.006
Lung Cancer
Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC
Respirology
Balasubramanian A, Geng J, Williams C, Rangamuwa K, John T
doi: 10.1002/resp.70238